B. Riley lowered the firm’s price target on Mirati Therapeutics to $45 from $51 and keeps a Neutral rating on the shares after the European Medicines Agency denied the conditional marketing authorization application for adagrasib for the treatment of KRAS G12C-mutated non-small cell lung cancer. However, the analyst thinks the probability is still in Mirati’s favor to show a statistically significant progression free survival benefit in the confirmatory study, as adagrasib and sotorasib have historically shown similar overall efficacy in their respective single-arm trials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics price target lowered to $46 from $54 at BofA
- Mirati Therapeutics price target lowered to $71 from $75 at Barclays
- Mirati announces EMA’s CHMP issued negative opinion on MAA for KRAZATI
- Mirati Therapeutics price target lowered to $42 from $51 at Morgan Stanley
- Mirati Therapeutics: JOCO publishes results from KRYSTAL-1 study of adagrasib